Aeterna Zentaris Announces Appointments to Board of Directors
January 29 2016 - 8:30AM
Business Wire
Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the “Company”)
today announced the appointment of Michael Cardiff and Ken Newport
to its Board of Directors, effective immediately, for a term to
expire at the Company’s upcoming 2016 annual meeting of
shareholders, whereupon it is anticipated that each of Messrs.
Cardiff and Newport will stand for election as director candidates
to be nominated by management.
Mr. Cardiff is the Chief Executive Officer of Accelerents, a
consulting firm focused on strategy development. Prior to holding
that position, Mr. Cardiff held numerous senior positions in a
number of technology companies, including large multinationals such
as EDS, SAP and IBM, as well as startup companies such as
Fincentric, Convergent Technologies, Tandem, and Stratus Computer.
Mr. Cardiff is currently a director of Hydrogenics
Corporation (NASDAQ: HYGS; TSX: HYG), and Startech.Com Mr.
Cardiff has also served as a director of publicly traded companies
including Husky Injection Molding, Descartes Systems Group, Visible
Genetics and Burntsand Inc. He has also been a director of private
companies including Solcorp, Spectra Security Software and Visible
Decisions and charitable organizations such as The Toronto Film
Festival, Roy Thomson Hall and Medic Alert Foundation. Mr. Cardiff
is a member of, and holds the ICD.D designation from, the Institute
of Corporate Directors.
A chartered accountant, entrepreneur and life-sciences business
executive, Mr. Newport served as Senior Vice-President and
Executive Committee member at PRA International Inc. for three
years until his retirement in 2005. He was co-founder and President
of CroMedica Inc., a clinical trials contract research
organization, which was sold to PRA International in 2002. Mr.
Newport was also a founding member of Global Biomedical Capital
Corporation, Zelos Therapeutics Inc., Prime Trials Inc. and other
life science organizations. He has served or serves on the
corporate Boards of Nordion Inc., The Opmedic Group, Jennerex Inc.
and Medgenesis Therapeutics Inc. He sits on several non-profit
boards, including his role as Chair of the BioCanRx, the National
Centre of Excellence for Biotherapeutics cancer research.
Commenting on the appointments, David A. Dodd, Chairman,
President and Chief Executive Officer of the Company, stated, “I am
delighted to welcome Mike and Ken to our Board. They bring
extensive capital markets and structuring and corporate development
experience, as well as a fresh perspective to our Company. I am
very much looking forward to working with them and to their
contributions as, together, we continue on our path of transforming
Aeterna Zentaris into a growth-oriented specialty biopharmaceutical
company.”
About the Company
Aeterna Zentaris is a specialty biopharmaceutical company
engaged in developing and commercializing novel treatments in
oncology, endocrinology and women’s health. We are engaged in drug
development activities and in the promotion of products for others.
We are now conducting Phase 3 studies of two internally developed
compounds. The focus of our business development efforts is the
acquisition of licenses to products that are relevant to our
therapeutic areas of focus. We also intend to license out certain
commercial rights of internally developed products to licensees in
territories where such out-licensing would enable us to ensure
development, registration and launch of our product candidates. Our
goal is to become a growth-oriented specialty biopharmaceutical
company by pursuing successful development and commercialization of
our product portfolio, achieving successful commercial presence and
growth, while consistently delivering value to our shareholders,
employees and the medical providers and patients who will benefit
from our products. For more information, visit www.aezsinc.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160129005110/en/
Aeterna Zentaris Inc.Philip A. Theodore, Senior Vice
President, 843-900-3223ir@aezsinc.com, www.aezsinc.com
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Sep 2023 to Sep 2024